This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids
by Zacks Equity Research
Vertex (VRTX) gains an EU approval for Orkambi to treat 2-5-year-old children suffering cystic fibrosis (CF).
Aerpio (ARPO) Jumps: Stock Rises 7.8%
by Zacks Equity Research
Aerpio (ARPO) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Nabriva Therapeutics (NBRV) Jumps: Stock Rises 6.7%
by Zacks Equity Research
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
by Zacks Equity Research
ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.
Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect
by Zacks Equity Research
Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.
Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9%
by Zacks Equity Research
Myriad Genetics (MYGN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Company News For Dec 26, 2018
by Zacks Equity Research
Companies In The News Are: AAPL,MB,TSLA,ACOR
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal
by Zacks Equity Research
It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.
Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija
by Zacks Equity Research
Acorda (ACOR) gains an FDA nod for its lead Parkinson's drug Inbrija pertaining to the treatment of OFF periods in patients afflicted with the disease.
Acorda (ACOR) Down 0.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acorda Down More Than 30% in the Past 3 Months: Here's Why
by Zacks Equity Research
Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States while its lead Parkinson disease candidate Inbrija's review timeline gets extended by three months.
Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up
by Zacks Equity Research
Acorda's (ACOR) Q3 rides high on earnings and revenue beat amid a strong generic competition for its MS drug Ampyra and the expected launch of its Parkinson's candidate, Inbrija.
Acorda Therapeutics (ACOR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Acorda (ACOR) delivered earnings and revenue surprises of 13.33% and 68.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Acorda Therapeutics (ACOR) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Acorda (ACOR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Centene's (CNC) Earnings and Revenues Top Estimates in Q3
by Zacks Equity Research
Execution of growth strategy as well as the company's solid operating metrics leads Centene (CNC) to an earnings beat in Q3.
Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija
by Zacks Equity Research
The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.
Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down
by Zacks Equity Research
Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra
Are Options Traders Betting on a Big Move in Acorda (ACOR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Acorda (ACOR) stock based on the movements in the options market lately.
Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda Therapeutics (ACOR) rides high on earnings as well as revenue beat in Q2.
Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.
Acorda Therapeutics (ACOR) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Acorda (ACOR) delivered earnings and revenue surprises of 86.67% and 19.10%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) is likely to witness solid growth in the core Pharmaceutical segment in Q4 results. However, lackluster performance in the Cordis unit is likely to mar prospects.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
Vertex Pharma (VRTX) is expected to beat estimates when it reports second-quarter earnings on Jul 25.